About CKLF-like MARVEL transmembrane domain-containing protein 4
CKLF-like MARVEL transmembrane domain-containing protein 4 (CMTM4) is a protein
from Homo sapiens identified by UniProt accession
Q8IZR5, 234 residues long.
MolForge cross-references it against 0 known binders and
176 disease associations.
Target properties
| Protein name | CKLF-like MARVEL transmembrane domain-containing protein 4 |
|---|
| UniProt accession | Q8IZR5 |
|---|
| Gene | CMTM4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 234 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (176)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.30
- body fat percentage · score 0.26
- serum alanine aminotransferase measurement · score 0.21
- low density lipoprotein triglyceride measurement · score 0.21
- aspartate aminotransferase measurement · score 0.21
- sex hormone-binding globulin measurement · score 0.21
- high density lipoprotein cholesterol measurement · score 0.21
- erythrocyte count · score 0.18
- hepatocellular carcinoma · score 0.10
- azoospermia · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IZR5-F1 | alphafold | PREDICTED | 73.86 | — |
Amino-acid sequence (234 residues)
MRSGEELDGF EGEASSTSMI SGASSPYQPT TEPVSQRRGL AGLRCDPDYL RGALGRLKVA QVILALIAFI CIETIMACSP CEGLYFFEFV SCSAFVVTGV LLIMFSLNLH MRIPQINWNL TDLVNTGLSA FLFFIASIVL AALNHRAGAE IAAVIFGFLA TAAYAVNTFL AVQKWRVSVR QQSTNDYIRA RTESRDVDSR PEIQRLDTFS YSTNVTVRKK SPTNLLSLNH WQLA
Explore CKLF-like MARVEL transmembrane domain-containing protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets